Role of Immune Checkpoint Inhibitors in Cervical Cancer: From Preclinical to Clinical Data
| Autor: | Camilla Nero, Simona Duranti, Giovanni Scambia, Antonella Pietragalla, Domenica Lorusso, Gennaro Daniele, Francesca Ciccarone |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Oncology PD-L1 Cancer Research medicine.medical_specialty cervical cancer medicine.medical_treatment Immune checkpoint inhibitors Review immune checkpoint inhibitors 03 medical and health sciences 0302 clinical medicine Immune system Internal medicine PD-1 medicine RC254-282 Cervical cancer CTLA4 biology business.industry Incidence (epidemiology) Neoplasms. Tumors. Oncology. Including cancer and carcinogens RELAPSED DISEASE Immunotherapy medicine.disease Clinical trial 030104 developmental biology 030220 oncology & carcinogenesis biology.protein immunotherapy business |
| Zdroj: | Cancers, Vol 13, Iss 2089, p 2089 (2021) Cancers |
| ISSN: | 2072-6694 |
| Popis: | Simple Summary Cervical cancer represents one of the main leading causes of cancer-related mortality in women worldwide. In contrast to patients with early-stage disease, those with advanced, recurrent, or metastatic cervical cancer have a poor prognosis and new treatment strategies are needed. Immunotherapy has recently modified the natural course of different tumors, such as melanoma and lung cancer. The aim of this review is to evaluate the possible role of immune checkpoint inhibitors in cervical cancer treatment. Abstract Human papillomavirus (HPV) infection is the recognized cause of almost all cervical cancers. Despite the reduction in incidence due to a wide use of screening programs and a specific vaccine, the prognosis of cervical cancer remains poor, especially for late-stage and relapsed disease. Considering the elevated rates of PD-L1 expression in up to 80% of cervical cancers, a strong rationale supports the use of immunotherapy to restore the immune response against tumor. The aim of this review is to analyze the possible role of immune checkpoint inhibitors in cervical cancer treatment, with a particular focus on the rationale and on the results of phase I and II clinical trials. An overview of ongoing phase III studies with possible future areas of development is also provided. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|